Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer

JAMA Surgery

Volumn 148, Issue 3, 2013, Pages 285-291

  Sitzmann, James V ^a   Wiebke, Eric A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; APPENDECTOMY; APPENDIX TUMOR; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CASE REPORT; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HUMAN; LOWER ABDOMINAL PAIN; META ANALYSIS; MUCOCELE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK REDUCING BILATERAL SALPINGOOOPHORECTOMY; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADULT; APPENDECTOMY; APPENDICEAL NEOPLASMS; FEMALE; GENES, BRCA1; HUMANS; PERITONEAL NEOPLASMS; RISK REDUCTION BEHAVIOR;

EID: 84875413005     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2013.1006     Document Type: Review

References (66)

1. Ford D, Easton DF, StrattonM, et al; Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62(3): 676-689. (Pubitemid 28164626)
2. Pichert G, Jacobs C, Jacobs I, et al. Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Fam Cancer. 2010;9(3): 313-319.
3. Buys SS, Partridge E, Black A, et al PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22): 2295-2303.
4. Meeuwissen PA, Seynaeve C, Brekelmans CT,Meijers-Heijboer HJ, Klijn JG, Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97(2): 476-482. (Pubitemid 40614892)
5. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30): 7491-7496. (Pubitemid 46291812)
6. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk-reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2): 80-87.
7. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21(22): 4222-4227. (Pubitemid 46606192)
8. Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 2002;20(6): 1570-1577. (Pubitemid 34260537)
9. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 cases. Cancer. 1989;64(1): 110-115. (Pubitemid 19167146)
10. Saluja M, Kenwright DN, Keating JP. Pseudomyxoma peritonei arising from a mucinous borderline ovarian tumour: case report and literature review. Aust N Z J Obstet Gynaecol. 2010;50(4): 399-403.
11. Domchek SM, Friebel TM, Garber JE, et al. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010;124(1): 195-203.
12. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23(1): 127-132. (Pubitemid 41702631)
13. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002; 87(1): 52-56. (Pubitemid 36027101)
14. Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Hum Pathol. 2012; 43(1): 1-16.
15. Ban S, Naitoh Y, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol. 2006;30(12): 1561-1569. (Pubitemid 44808792)
16. Sjo OH, Berg M, Merok MA, et al. Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors. J Surg Oncol. 2011;104(7): 792-797.
17. Yates MS, Meyer LA, Deavers MT, et al. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila). 2011;4(3): 463-470.
18. Menczer J, Chetrit A, Barda G, et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol. 2003;88(1): 58-61. (Pubitemid 36062666)
19. Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009;33(8): 1125-1136.
20. Grant DJ, Moorman PG, Akushevich L, Palmieri RT, Bentley RC, Schildkraut JM. Primary peritoneal and ovarian cancers: an epidemiological comparative analysis. Cancer Causes Control. 2010;21(7): 991-998.
21. Laki F, Kirova YM, This P, et al IC-BOCRSG (Institut Curie-Breast Ovary Cancer Risk Study Group). Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer. 2007;109(9): 1784-1790. (Pubitemid 46668541)
22. Finch A, Metcalfe K, Lui J, et al. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene. Clin Genet. 2009;75(3): 220-224.
23. Finch A, Beiner M, Lubinski J, et al Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2): 185-192.
24. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002; 20(5): 1260-1268. (Pubitemid 34177432)
25. Olivier RI, van Beurden M, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90(8): 1492-1497. (Pubitemid 38648227)
26. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl JMed. 2002; 346(21): 1609-1615. (Pubitemid 34755668)
27. Rebbeck TR, Lynch HT, Neuhausen SL, et al Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21): 1616-1622. (Pubitemid 34755669)
28. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo- oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011;21(5): 846-851.
29. Maehle L, Apold J, Paulsen T, et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin Cancer Res. 2008;14 (22): 7569-7573.
30. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304(9): 967-975.
31. Rutter JL, Wacholder S, Chetrit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst. 2003;95(14): 1072-1078. (Pubitemid 36950111)
32. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8): 1331-1337.
33. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005;97(2): 457-467. (Pubitemid 40614890)
34. Rhiem K, Foth D, Wappenschmidt B, et al. Risk-reducing salpingooophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet. 2011; 283(3): 623-627.
35. Bellera CA, MacGrogan G, Debled M, de Lara CT, Brouste V, Mathoulin-Pélissier S. Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol. 2010;10:20. doi:10.1186/1471-2288-10-20.
36. Crowther MJ, Riley RD, Staessen JA, Wang J, Gueyffier F, Lambert PC. Individual patient data meta-analysis of survival data using Poisson regression models. BMC Med Res Methodol. 2012;12:34. doi:10.1186/1471-2288-12-34.
37. Lawless JF. Statistical Models and Methods for Lifetime Data. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2003.
38. Schluchter MD. Methods for the analysis of informatively censored longitudinal data. Stat Med. 1992;11(14-15): 1861-1870. (Pubitemid 23015635)
39. Piver MS. Prophylactic oophorectomy: reducing the US death rate from epithelial ovarian cancer: a continuing debate. Oncologist. 1996;1(5): 326-330.
40. Casey MJ, Bewtra C. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Fam Cancer. 2004;3(3-4): 265-281. (Pubitemid 39491744)
41. Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet. 2009;17(11): 1381-1385.
42. Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer. 2009;8(1): 23-28.
43. Genadry R, Poliakoff S, Rotmensch J, Rosenshein NB, Parmley TH, Woodruff JD. Primary, papillary peritoneal neoplasia. Obstet Gynecol. 1981;58(6): 730-734. (Pubitemid 12235700)
44. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006;194(6): 1702-1709. (Pubitemid 43766909)
45. Arienti C, Tesei A, Verdecchia GM, et al. Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J Transl Med. 2011;9:94. doi:10.1186/1479-5876-9-94.
46. Gourley C, Michie CO, Roxburgh P, et al. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010;28(15): 2505-2511.
47. Eitan R, Soslow R, Lin O, et al. The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2006;102(2): 315-318. (Pubitemid 44041643)
48. Lo NS, Sarr MG. Mucinous cystadenocarcinoma of the appendix: the controversy persists: a review. Hepatogastroenterology. 2003;50(50): 432-437. (Pubitemid 36390538)
49. Giardiello FM, Offerhaus JG. Phenotype and cancer risk of various polyposis syndromes. Eur J Cancer. 1995;31A(7-8): 1085-1087.
50. Bussey HJ. Familial Polyposis Coli: Family Studies, Histopathology, Differential Diagnosis, and Results of Treatment. Baltimore, MD: Johns Hopkins University Press; 1975.
51. Burt RW, LeppertMF, Slattery ML, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology. 2004; 127(2): 444-451. (Pubitemid 39091892)
52. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110(4): 1020-1027. (Pubitemid 26113739)
53. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009; 137(5): 1621-1627.
54. Aretz S, Uhlhaas S, Goergens H, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer. 2006;119(4): 807-814. (Pubitemid 44051443)
55. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10): 3209-3215. (Pubitemid 43837371)
56. Coburn MC, Pricolo VE, DeLuca FG, Bland KI. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol. 1995;2(5): 386-391.
57. Desai DC, Neale KF, Talbot IC, Hodgson SV, Phillips RK. Juvenile polyposis. Br J Surg. 1995;82(1): 14-17.
58. Chand M, Moore PJ, Clarke AD, Nash GF, Hickisk T. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation: a case report of primary papillary serous carcinoma presenting as sigmoid cancer. World J Surg Oncol. 2007; 5:102. doi:10.1186/1477-7819-5-102. (Pubitemid 350111691)
59. Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134(6): 864-870.
60. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009. eds National Cancer Institute website. http://seer.cancer.gov/csr /1975-2009-pops09/sections.html. Updated 2012. Accessed August 15, 2012.
61. Goodman MT, Shvetsov YB. Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact? Int J Cancer. 2009; 124(9): 2231-2235.
62. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer. 1995;75(1)(suppl): 154-170.
63. Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33(10): 1425-1439.
64. Hale DA, Molloy M, Pearl RH, Schutt DC, Jaques DP. Appendectomy: a contemporary appraisal. Ann Surg. 1997;225(3): 252-261. (Pubitemid 27131560)
65. Salom EM, Schey D, Pen?alver M, et al. The safety of incidental appendectomy at the time of abdominal hysterectomy. Am J Obstet Gynecol. 2003;189(6): 1563-1568. (Pubitemid 38056424)
66. O'Hanlan KA, Fisher DT, O'Holleran MS. 257 Incidental appendectomies during total laparoscopic hysterectomy. JSLS. 2007;11(4): 428-431.